Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Income towards Parent Company (2019 - 2025)

Historic Income towards Parent Company for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$78.2 million.

  • Nurix Therapeutics' Income towards Parent Company fell 3359.92% to -$78.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$264.5 million, marking a year-over-year decrease of 3662.16%. This contributed to the annual value of -$264.5 million for FY2025, which is 3662.16% down from last year.
  • As of Q4 2025, Nurix Therapeutics' Income towards Parent Company stood at -$78.2 million, which was down 3359.92% from -$86.4 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Income towards Parent Company peaked at -$24.3 million during Q1 2021, and registered a low of -$86.4 million during Q3 2025.
  • For the 5-year period, Nurix Therapeutics' Income towards Parent Company averaged around -$45.0 million, with its median value being -$43.0 million (2022).
  • Per our database at Business Quant, Nurix Therapeutics' Income towards Parent Company crashed by 44804.75% in 2021 and then surged by 4652.76% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Income towards Parent Company (Quarter) stood at -$37.7 million in 2021, then decreased by 23.95% to -$46.7 million in 2022, then rose by 10.19% to -$42.0 million in 2023, then tumbled by 39.55% to -$58.5 million in 2024, then plummeted by 33.6% to -$78.2 million in 2025.
  • Its Income towards Parent Company was -$78.2 million in Q4 2025, compared to -$86.4 million in Q3 2025 and -$43.5 million in Q2 2025.